Makaleler
190
Tümü (190)
SCI-E, SSCI, AHCI (168)
SCI-E, SSCI, AHCI, ESCI (175)
ESCI (4)
Scopus (184)
TRDizin (16)
Diğer Yayınlar (2)
3. Effect of Telerehabilitation-Based Motor Imagery Training on Pain and Related Factors in People With Multiple Sclerosis: Randomized Controlled Pilot Trial
Archives of Physical Medicine and Rehabilitation
, cilt.106, sa.4, ss.562-572, 2025 (SCI-Expanded, Scopus)
11. Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry
Journal of Neurology, Neurosurgery and Psychiatry
, cilt.95, sa.7, ss.620-625, 2024 (SCI-Expanded, Scopus)
21. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
Journal of neurology, neurosurgery, and psychiatry
, cilt.94, sa.12, ss.1004-1011, 2023 (SCI-Expanded, Scopus)
22. Risk of secondary progressive multiple sclerosis after early worsening of disability
Journal of Neurology, Neurosurgery and Psychiatry
, cilt.94, sa.12, ss.984-991, 2023 (SCI-Expanded, Scopus)
25. Feasibility of Telerehabilitation-Based Pelvic Floor Muscle Training for Urinary Incontinence in People With Multiple Sclerosis: A Randomized, Controlled, Assessor-Blinded Study
Journal of neurologic physical therapy : JNPT
, cilt.47, sa.4, ss.217-226, 2023 (SCI-Expanded, Scopus)
26. Disability accrual in primary and secondary progressive multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry
, cilt.94, ss.707-717, 2023 (SCI-Expanded, Scopus)
36. Effects of prolonged walking on dual-task walking performance in persons with multiple sclerosis
MULTIPLE SCLEROSIS JOURNAL
, ss.67, 2023 (SCI-Expanded, Scopus)
37. Association between work-related difficulties and dual-task ability in people with multiple sclerosis
MULTIPLE SCLEROSIS JOURNAL
, ss.54-55, 2023 (SCI-Expanded, Scopus)
43. Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
, cilt.94, sa.1, ss.23-30, 2023 (SCI-Expanded, Scopus)
47. Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
, cilt.93, sa.12, ss.1322-1329, 2022 (SCI-Expanded, Scopus)
48. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
, cilt.93, sa.12, ss.1330-1337, 2022 (SCI-Expanded, Scopus)
52. Factors related to restless leg syndrome in neuromyelitis optica spectrum disorder
MULTIPLE SCLEROSIS JOURNAL
, cilt.28, sa.3_SUPPL, ss.1008, 2022 (SCI-Expanded, Scopus)
53. Predictive ability of the original and short form of the activities-specific balance confidence scale and its individual items for falls in people with multiple sclerosis
MULTIPLE SCLEROSIS JOURNAL
, cilt.28, sa.3_SUPPL, ss.407-408, 2022 (SCI-Expanded, Scopus)
58. Comparison of late-onset and early-onset people with multiple sclerosis based on cognitive and physical assessments
EUROPEAN JOURNAL OF NEUROLOGY
, cilt.29, ss.640, 2022 (SCI-Expanded, Scopus)
59. Comparative Effectiveness and Persistence of Cladribine Tablets from GLIMPSE: Results from the MSBase Registry
EUROPEAN JOURNAL OF NEUROLOGY
, cilt.29, ss.289-290, 2022 (SCI-Expanded, Scopus)
61. Comparison of cognitive functions in relapsing and progressive multiple sclerosis patients on ocrelizumab treatment
MULTIPLE SCLEROSIS JOURNAL
, cilt.28, sa.2_SUPPL, ss.9, 2022 (SCI-Expanded, Scopus)
62. Sustained attention during prolonged walking in persons with multiple sclerosis
MULTIPLE SCLEROSIS JOURNAL
, cilt.28, sa.2_SUPPL, ss.14-15, 2022 (SCI-Expanded, Scopus)
66. Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry
MULTIPLE SCLEROSIS JOURNAL
, cilt.28, sa.1_SUPPL, ss.176-177, 2022 (SCI-Expanded, Scopus)
77. Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national cohort
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.746-747, 2021 (SCI-Expanded, Scopus)
78. Relationship between presence of spinal cord lesion and restless legs syndrome in multiple sclerosis
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.259, 2021 (SCI-Expanded, Scopus)
79. Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.558-559, 2021 (SCI-Expanded, Scopus)
80. Effect of exergaming in persons with multiple sclerosis with restless legs syndrome: a randomized controlled trial
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.723, 2021 (SCI-Expanded, Scopus)
81. Real-world experience with ocrelizumab in relapsing multiple sclerosis: insights from the MSOCR-R cohort, an MSBase registry sub-study
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.104-106, 2021 (SCI-Expanded, Scopus)
82. Comparatve effectveness of beta-nterferons and glatramer acetate on physcal and cogntve functons: 6-month follow-up study
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.631-632, 2021 (SCI-Expanded, Scopus)
83. Comparison of early treatment response of ocrelizumab in relapsing and progressive multiple sclerosis patients on the basis of cognitive functions
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.276, 2021 (SCI-Expanded, Scopus)
84. Comparative analysis of early treatment effectiveness of first-line disease-modifying therapies and fingolimod on cognitive functions in persons with multiple sclerosis
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.566-567, 2021 (SCI-Expanded, Scopus)
86. Real-world experience with cladribine in the MSBase Registry
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.681-683, 2021 (SCI-Expanded, Scopus)
88. Does the reason for the switch to fingolimod affect the treatment response?
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.585, 2021 (SCI-Expanded, Scopus)
89. Relapse during the washout period predicts time to relapse after switching to cladribine
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.706-707, 2021 (SCI-Expanded, Scopus)
90. Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.778-780, 2021 (SCI-Expanded, Scopus)
91. External validation of the MSBase model of individual treatment response (Crystal Ball 1.0)
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.753-754, 2021 (SCI-Expanded, Scopus)
92. Cognition as a parameter that should not be ignored when evaluating the effect of relapse treatment: A prospective controlled study
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.662-663, 2021 (SCI-Expanded, Scopus)
93. Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.2_SUPPL, ss.673-676, 2021 (SCI-Expanded, Scopus)
105. Delay from treatment start to full effect of immunotherapies for multiple sclerosis
NEUROLOGY
, cilt.96, sa.15, 2021 (SCI-Expanded, Scopus)
106. Assessment of brain atrophy and lesion burden with clinical outcomes in multiple sclerosis real-world practice: The NeuroSTREAM MSBase retrospective, longitudinal study
NEUROLOGY
, cilt.96, sa.15, 2021 (SCI-Expanded, Scopus)
107. High and low efficacy therapy in secondary progressive multiple sclerosis
NEUROLOGY
, cilt.96, sa.15, 2021 (SCI-Expanded, Scopus)
109. Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis
NEUROLOGY
, cilt.96, sa.15, 2021 (SCI-Expanded, Scopus)
111. Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis
NEUROLOGY
, cilt.96, sa.15, 2021 (SCI-Expanded, Scopus)
113. Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts
NEUROLOGY
, cilt.96, sa.15, 2021 (SCI-Expanded, Scopus)
131. Monthly Pulse Methylprednisolone Therapy is Effective in Preventing Permanent Disease Progression in Secondary Progressive Multiple Sclerosis
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
, cilt.56, sa.2, ss.115-118, 2019 (SCI-Expanded, Scopus, TRDizin)
132. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
, cilt.90, sa.4, ss.458-468, 2019 (SCI-Expanded, Scopus)
135. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
, cilt.321, sa.2, ss.175-187, 2019 (SCI-Expanded, Scopus)
143. Prediction of Conversion from Clinically Isolated Syndrome to Multiple Sclerosis According to Baseline Characteristics: A Prospective Study
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
, cilt.55, sa.1, ss.15-21, 2018 (SCI-Expanded, Scopus, TRDizin)
168. The Comparison of Physical Activity Status, Exercise Perception and Quality of Life Between Clinically Isolated Syndrome and Multiple Sclerosis Patients
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
, cilt.50, sa.2, ss.116-121, 2013 (SCI-Expanded, Scopus, TRDizin)
169. The Effects of Low and Severe Disability on Walking Abilities and Quality of Life in Multiple Sclerosis Patients: 6-Month Follow-up Study
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
, cilt.50, sa.1, ss.23-29, 2013 (SCI-Expanded, Scopus, TRDizin)
173. Quality of Life, Fatigue and Balance Improvements after Home-Based Exercise Program in Multiple Sclerosis Patients
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
, cilt.49, sa.1, ss.33-38, 2012 (SCI-Expanded, Scopus, TRDizin)
174. Symptomatic Menagement in Multiple Sclerosis
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
, cilt.48, ss.83-89, 2011 (SCI-Expanded, Scopus, TRDizin)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
128
2. A Multi-Country Comparative Effectiveness Study of Dimethyl Fumarate and Non-Specific Immunosuppressants in a Real-World Setting: Evidence from MSBase
Pan-Asian Committee on Treatment and Research in Multiple Sclerosis (PACTRIMS), Perth, Avustralya, 23 - 25 Kasım 2022, (Özet Bildiri)
7. Early Predictors of Disability in Paediatric Multiple Sclerosis: Evidence from a Multi -National Registry
Annual Meeting of the American-Academy-of-Neurology, Washington, Amerika Birleşik Devletleri, 2 - 07 Nisan 2022, (Özet Bildiri)
9. Long-term outcomes in patients presenting with optic neuritis: analyses of the MSBase registry
37th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), ELECTR NETWORK, 13 - 15 Ekim 2021, cilt.27, ss.103-104, (Özet Bildiri)
11. Disability accrual in primary-progressive & secondary-progressive multiple sclerosis
8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), ELECTR NETWORK, 11 - 13 Eylül 2020, cilt.26, ss.527-528, (Özet Bildiri)
12. High and low efficacy therapy in secondary progressive multiple sclerosis after accounting for therapeutic lag
8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), ELECTR NETWORK, 11 - 13 Eylül 2020, cilt.26, ss.534-535, (Özet Bildiri)
13. Real-world experience with ocrelizumab in the msbase registry
8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), ELECTR NETWORK, 11 - 13 Eylül 2020, cilt.26, ss.550-551, (Özet Bildiri)
19. Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.912-914, (Özet Bildiri)
20. Aggressive form of multiple sclerosis can be predicted early after disease onset
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.605-607, (Özet Bildiri)
22. Real-world experience with Ocrelizumab in the MSBase Registry
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.539-540, (Özet Bildiri)
23. The relationship between cognition, depression, fatigue, and disability in patients with multiple sclerosis
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.206, (Özet Bildiri)
26. Changes in cognitive functions after disease-modifying therapies switching in persons with multiple sclerosis
Annual Conference of Rehabilitation in Multiple Sclerosis (RIMS) - Crossing the Interface to Explore New Possibilities, Ljubljana, Slovenya, 20 - 22 Haziran 2019, cilt.25, ss.1050, (Özet Bildiri)
27. Factors related to dual-task cost of walking in persons with multiple sclerosis
Annual Conference of Rehabilitation in Multiple Sclerosis (RIMS) - Crossing the Interface to Explore New Possibilities, Ljubljana, Slovenya, 20 - 22 Haziran 2019, cilt.25, ss.1049-1050, (Özet Bildiri)
28. Adherence to treatment in multiple sclerosis
Annual Conference of Rehabilitation in Multiple Sclerosis (RIMS) - Crossing the Interface to Explore New Possibilities, Ljubljana, Slovenya, 20 - 22 Haziran 2019, cilt.25, ss.1053, (Özet Bildiri)
29. Effects of first-line and second-line disease-modifying therapies on cognitive function in persons with multiple sclerosis
Annual Conference of Rehabilitation in Multiple Sclerosis (RIMS) - Crossing the Interface to Explore New Possibilities, Ljubljana, Slovenya, 20 - 22 Haziran 2019, cilt.25, ss.1052-1053, (Özet Bildiri)
30. A comparison of the effects of oral versus injection disease-modifying therapies on cognition in persons with multiple sclerosis
Annual Conference of Rehabilitation in Multiple Sclerosis (RIMS) - Crossing the Interface to Explore New Possibilities, Ljubljana, Slovenya, 20 - 22 Haziran 2019, cilt.25, ss.1051, (Özet Bildiri)
31. Efficacy of switching disease-modifying therapies on walking in persons with multiple sclerosis
Annual Conference of Rehabilitation in Multiple Sclerosis (RIMS) - Crossing the Interface to Explore New Possibilities, Ljubljana, Slovenya, 20 - 22 Haziran 2019, cilt.25, ss.1051, (Özet Bildiri)
32. Walking and balance in relation to depression and fatigue in persons with multiple sclerosis
Annual Conference of Rehabilitation in Multiple Sclerosis (RIMS) - Crossing the Interface to Explore New Possibilities, Ljubljana, Slovenya, 20 - 22 Haziran 2019, cilt.25, ss.1052, (Özet Bildiri)
38. Familial multiple sclerosis: comparing demographic and clinical characteristics with sporadic form.
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.24-25, (Özet Bildiri)
44. Multipl sklerozlu bireylerde ağrının sıklığı, tipi, dağılımı ve ağrıyla ilişkili etmenler
XVII. Fizyoterapi ve Rehabilitasyonda Gelişmeler Kongresi, Türkiye, 25 - 28 Nisan 2018, cilt.29, (Özet Bildiri) 
57. The effects of clinical Pilates training on walking, balance, fall risk, respiratory and cognitive functions in persons with multiple sclerosis: a randomized controlled trial
23rd Annual Conference of Rehabilitation in Multiple Sclerosis (RIMS), Amsterdam, Hollanda, 31 Mayıs - 02 Haziran 2018, cilt.24, ss.862, (Özet Bildiri)
58. Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry
70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)
59. Extremities and Cognition: Fampridine Effect
ACTRIMS Forum, California, Amerika Birleşik Devletleri, 1 - 03 Şubat 2018, cilt.24, ss.139-140, (Özet Bildiri)
65. The effect of fampridine treatment on cognition: two year prospective study
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.412-413, (Özet Bildiri)
66. Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.325-327, (Özet Bildiri)
67. Risk of secondary progressive multiple sclerosis: a longitudinal study
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.109-112, (Özet Bildiri)
68. The 20-year history: change of multiple sclerosis patient profile over 20 years
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.896-897, (Özet Bildiri)
71. Restless legs syndrome and related factors in persons with multiple sclerosis
22nd Annual RIMS Conference on Shaping the Future of MS Rehabilitation, Barcelona, İspanya, 4 - 06 Mayıs 2017, cilt.23, ss.907, (Özet Bildiri)
72. The Multiple Sclerosis Work Difficulties Questionnaire: Translation and cross-cultural adaptation into Turkish and assessment of validity and reliability
22nd Annual RIMS Conference on Shaping the Future of MS Rehabilitation, Barcelona, İspanya, 4 - 06 Mayıs 2017, cilt.23, ss.906, (Özet Bildiri)
73. Balance related explanatory factors of the six-minute walk test in persons with multiple sclerosis
22nd Annual RIMS Conference on Shaping the Future of MS Rehabilitation, Barcelona, İspanya, 4 - 06 Mayıs 2017, cilt.23, ss.906, (Özet Bildiri)
74. The immediate effects of a patient education meeting on health locus of control of persons with multiple sclerosis and their family members
22nd Annual RIMS Conference on Shaping the Future of MS Rehabilitation, Barcelona, İspanya, 4 - 06 Mayıs 2017, cilt.23, ss.894-895, (Özet Bildiri)
75. Effects of a 6-month yoga program on physical and psychosocial status in persons with multiple sclerosis
22nd Annual RIMS Conference on Shaping the Future of MS Rehabilitation, Barcelona, İspanya, 4 - 06 Mayıs 2017, cilt.23, ss.894, (Özet Bildiri)
76. OTHER The presence of musculoskeletal pain and its distribution among the body regions in persons with multiple sclerosis: a preliminary study
22nd Annual RIMS Conference on Shaping the Future of MS Rehabilitation, Barcelona, İspanya, 4 - 06 Mayıs 2017, cilt.23, ss.915-916, (Özet Bildiri)
83. Effects of Fingolimod on Cognitive Status in Patients with Multiple Sclerosis: Prospective, Controlled Trial
68th Annual Meeting of the American-Academy-of-Neurology (AAN), Vancouver, Kanada, 15 - 21 Nisan 2016, cilt.86, (Özet Bildiri)
84. Core stability is associated with walking balance andfalls in people with multiple sclerosis a pilot study
nternational Neurology and Rehabilitation Meeting(INeReM), İSTANBUL, 4 - 06 Haziran 2015, (Özet Bildiri)
96. THE EFFECT OF WALKING IMPAIRMENT OF MULTIPLE SCLEROSIS PATIENTS ON CAREGIVER BURDEN
18th Annual Meeting of Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Florida, Amerika Birleşik Devletleri, 31 Mayıs - 01 Haziran 2013, cilt.19, ss.1402, (Özet Bildiri)
97. Inflammatory Demyelinating Central Nervous System Diseases in Childhood: Clinical and Paraclinical Profiles in 133 Patients
65th Annual Meeting of the American-Academy-of-Neurology (AAN), California, Amerika Birleşik Devletleri, 16 - 23 Mart 2013, cilt.80, (Özet Bildiri)
104. Do neutralizing antibodies affect interferon beta treatment based on multiple sclerosis functional composite? Preliminary results
20th Meeting of the European-Neurological-Society, Berlin, Almanya, 19 - 23 Haziran 2010, cilt.257, (Özet Bildiri)
107. Do neutralising antibodies affect interferon-beta treatment based on multiple sclerosis functional composite? Preliminary results
25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Düsseldorf, Almanya, 9 - 12 Eylül 2009, cilt.15, (Özet Bildiri)
110. Sexual Dysfunction in Multiple Sclerosis: Gender Basis Differences
61st Annual Meeting of American-Academy-of-Neurology, Washington, Amerika Birleşik Devletleri, 28 - 29 Nisan 2009, cilt.72, (Özet Bildiri)
114. Comparison of optic-spinal multiple sclerosis with conventional multiple sclerosis: clinical and laboratory features
13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, Montreal, Kanada, 17 - 20 Eylül 2008, cilt.14, (Özet Bildiri)
115. Sexual dysfunction in multiple sclerosis
13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, Montreal, Kanada, 17 - 20 Eylül 2008, cilt.14, (Özet Bildiri)
119. Lhermitte's sign in multiple sclerosis: Neuroradiological correlation
60th Annual Meeting of the American-Academy-of-Neurology, Illinois, Amerika Birleşik Devletleri, 12 - 19 Nisan 2008, cilt.70, (Özet Bildiri)
127. Utilisation of the Multiple Sclerosis Functional Composite in follow-up: relationship to disease phenotype, disability and treatment strategies
20th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/9th Annual Meeting of Rehabilitation in MS, Vienna, Avusturya, 6 - 09 Ekim 2004, cilt.10, (Özet Bildiri)
128. Utilisation of Auditory Consonant Trigram test to screen for cognitive impairment in patients with multiple sclerosis: comparison with the Paced Auditory Serial Addition Test
20th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple- Sclerosis/9th Annual Meeting of Rehabilitation in MS, Vienna, Avusturya, 6 - 09 Ekim 2004, cilt.10, (Özet Bildiri)
Kitaplar
1
Metrikler
Yayın
337
Açık Erişim
37
BM Sürdürülebilir Kalkınma Amaçları
